Summary by Moomoo AI
On January 19, 2024, Altamira Therapeutics Ltd. announced the initiation of an At the Market Offering Agreement with H.C. Wainwright & Co., LLC, to offer and sell its common shares at a total value of up to $1.66 million. The sales will be conducted on an 'at the market' basis, meaning they will be sold at prevailing market prices through the Nasdaq Capital Market or other trading platforms. H.C. Wainwright & Co. will receive a commission of 3.0% on the gross sales price of the shares sold. The offering is not bound by minimum sale requirements, and the total number of shares sold and the net proceeds to Altamira Therapeutics are not yet determinable. The offering will conclude once the total sales reach $1.66 million or upon termination of the agreement by either party. This follows the company's termination of a previous at-the-market offering program with A.G.P./Alliance Global Partners in December 2023, where approximately $13.06 million worth of common shares were sold.